Amstrupharrison3266

Patient safety research is expanding from hospitals to community-based healthcare settings. Knowledge gaps persist among manual therapy professions that may impede patient safety initiatives within musculoskeletal care settings.

To describe perceptions of patient safety among chiropractors and physiotherapists who provide spinal manipulation therapy (SMT).

Qualitative descriptive study.

Cross-sectional data were collected using the SafetyNET Survey to Support Quality Improvement. SMT providers (n=705) in 3 countries completed surveys, with 84 providing written responses to an open-ended question about patient safety. Qualitative thematic analysis described providers' perceptions about patient safety within their practice.

SMT providers' perceptions were influenced by professional, patient, and practice setting factors. Five themes and 10 supporting categories were developed. Doing Our Best for Patient Safety concerned Avoiding Mistakes and Prioritizing Safety.Putting Patients First focused on Develohat the nature of healthcare settings influence patient safety strategies. Most responses focused on individual strategies to prevent adverse events. However, this approach may overlook the benefits of identifying and documenting adverse events, setting time to discuss adverse events with clinic members, standardizing clinical practices, and building transparent patient safety cultures across healthcare professions and settings.

Testing men for HIV during their partner's pregnancy can guide couples-based HIV prevention and treatment, but testing rates remain low. We investigated a combination approach, using evidence-based strategies, to increase HIV testing in male partners of HIV-positive and HIV-negative pregnant women.

We did two parallel, unmasked randomised trials, enrolling pregnant women who had an HIV-positive test result documented in their antenatal record (trial 1) and women who had an HIV-negative test result documented in their antenatal record (trial 2) from an antenatal setting in Lusaka, Zambia. Women in both trials were randomly assigned (11) to the intervention or control groups using permuted block randomisation. The control groups received partner notification services only, including an adapted version for women who were HIV-negative; the intervention groups additionally received targeted education on the use of oral HIV self-test kits for their partners, along with up to five oral HIV self-test kits. At thee, including for HIV prevention, and should be considered in the design of comprehensive HIV programmes.

National Institutes of Health.

National Institutes of Health.

Patients with chronic lymphocytic leukaemia who progress to Richter transformation (diffuse large B-cell lymphoma morphology) have few therapeutic options. We analysed data from the Richter transformation cohort of a larger, ongoing, phase 1-2, single-arm study evaluating the safety and activity of the selective, irreversible Bruton's tyrosine kinase inhibitor acalabrutinib for the treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma.

For this open-label, single-arm, phase 1-2 study, patients aged 18 years or older with biopsy-proven treatment-naive or previously treated diffuse large B-cell lymphoma (Richter transformation) or prolymphocytic leukaemia transformation (Eastern Cooperative Oncology Group performance status ≤2) were assigned to receive oral acalabrutinib 200 mg twice daily as monotherapy until disease progression or toxicity. Patients were enrolled across seven centres from four countries. Safety and pharmacokinetics were assessed as primary endpoints; secondary endpointsa Group.

Acerta Pharma, a member of the AstraZeneca Group.IR825 is a kind of near-infrared (NIR) small molecule cyanine dye and has distinct near-infrared absorbance and excellent thermal conversion performance. Due to poor stability and insufficient therapy efficacy, various nano-systems have been developed as delivery vehicles for NIR dyes to improve their application in tumor treatment. Herein, we developed an intelligent polymer drug vehicle (Mal-PAH-PEG-DMMA/ poly (ethylene imine) - poly(ε-caprolactone) block polymers, MPPD/PEI-PCL) based on pH-responsive charge-reversal to deliver docetaxel (DTX) and photosensitizer (IR825) for chemo-photothermal combination therapy (MPPD@IR825/DTX NPs). MPPD@IR825/DTX NPs could undergo charge conversion in a slightly acidic microenvironment (pH 6.8), resulted in strong electrostatic repulsion to withdraw the shell of the polymer nanoparticles (MPPD), enhanced cellular uptake and increased drug release. MPPD@IR825/DTX NPs demonstrated nanoscale in size with good mono-dispersity and stability, triggered DTX release in response to acid environment and NIR stimulation, in the same time providing excellent photothermal conversion efficiency. In vitro and In vivo experiments confirmed that charge-reversal polymeric nanoparticles improved antitumor efficiency in 4T1 tumor cell modal than non-charge-reversal polymeric nanoparticles. Furthermore, in comparison with chemotherapy or photothermal therapy in a single treatment mode, chemo-photothermal combination therapy of MPPD@IR825/DTX NPs with laser irradiation showed highly efficient tumor ablation. In addition, the polymeric nanoparticles exhibited good biocompatibility and safety. Therefore, the design of charge-reversal polymeric nanoparticles (MPPD@IR825/DTX NPs) provides a new strategy and promising application for targeting and synergistic chemo-photothermal combination therapy.Cycloastragenol (CA) is a plant saponin that functions as a telomerase activator, and it has been made as an oral anti-aging supplement and use as active ingredient in topical cosmetic products. Selleck Ripasudil The anti-aging performance in cosmetic products have only been evaluated by description of skin appearance, while direct topical penetration of CA across the skin barrier still needs to be confirmed. The objective of this work was to design encapsulation vehicles to deliver CA across the skin barrier using commercially available ingredients through scalable processes, and to prove its topical penetration. Phospholipid vesicles including liposomes, ethosomes, and transethosomes were prepared using soy and sunflower phospholipids and different penetration enhancers, including ethanol and surfactants. The loading capacity of CA was analyzed using high performance liquid chromatography, and the topical penetration of CA was evaluated using Franz diffusion cells with pig skin. Transethosomes using Tween 80, Span 40, or dicetylphosphate as the penetration enhancer showed better CA delivery across the skin barrier than ethosomes or emulsifier α-gels. Results of this work provide evidence that CA encapsulated in phospholipid vesicles can be transported across the skin barrier. These encapsulation systems could be used for the design of CA-containing anti-aging cosmetic products.Doping Mn2+ into CsPbCl3 nanocrystals (NCs) yields strong orange emission, while the related emission in Mn2+ doped CsPbBr3 NCs is impaired seriously. This is mainly ascribed to back energy transfer from the Mn2+ dopant to the host. Doping Mn2+ into perovskites with multiple-quantum-well (MQW) structures may address this issue, where the energy funnels ensure a rapid energy transfer process, and thus resulting in a high photoluminescence quantum yield (PLQY). Here, we have developed an Ag+ assisted Mn2+ doping method in which Mn2+ can be easily doped into Br-based MQW perovskites. In this MQW perovskites, both nanoplatelets (NPLs) and NCs were formed simultaneously, where efficient energy transfer occurred from the NPLs with a higher energy bandgap to the NCs with a smaller energy bandgap, and then to the Mn2+ dopants. White lighting solution with a PLQY up to 98% has been acquired by altering the experimental parameters, such as reaction time and the Pb-to-Mn feed ratio. The successful doping of Mn2+ into CsPbBr3 host has great significance and shows promising application for next-generation white lighting.

Stabilization of water-in-water (W/W) emulsions resulting from the separation of polymeric phases such as dextran (DEX) and poly(ethyleneoxide) (PEO) is highly challenging, because of the very low interfacial tensions between the two phases and because of the interface thickness extending over several nanometers. In the present work, we present a new type of stabilizers, based on bis-hydrophilic, thermoresponsive microgels, incorporating in the same structure poly(N-isopropylacrylamide) (pNIPAM) chains having an affinity for the PEO phase and dextran moieties. We hypothesize that these particles allow better control of the stability of the W/W emulsions.

The microgels were synthesized by copolymerizing the NIPAM monomer with a multifunctional methacrylated dextran. They were characterized by dynamic light scattering, zeta potential measurements and nuclear magnetic resonance as a function of temperature. Microgels with different compositions were tested as stabilizers of droplets of the PEO phase disperseabilized better D/P emulsions. However, above the volume phase transition temperature (VPTT ≈ 32 °C) of pNIPAM the microgels shrunk and stabilized better P/D emulsions. At all temperatures, excess microgels partitioned more to the PEO phase. The change in structure and interparticle interaction induced by heating can be exploited to control the W/W emulsion stability.Ionic liquids (ILs) have been used in solvents for proteins in many applications, including biotechnology, pharmaceutics, and medicine due to their tunable physicochemical and biological properties. Protein aggregation is often undesirable, and predominantly occurs during bioprocesses, while the aggregation process can be reversible or irreversible and the aggregates formed can be native/non-native and soluble/insoluble. Recent studies have clearly identified key properties of ILs and IL-water mixtures related to protein performance, suggesting the use of the tailorable properties of ILs to inhibit protein aggregation, to promote protein crystallization, and to control protein aggregation pathways. This review discusses the critical properties of IL and IL-water mixtures and presents the latest understanding of the protein aggregation pathways and the development of IL systems that affect or control the protein aggregation process. Through this feature article, we hope to inspire further advances in understanding and new approaches to controlling protein behavior to optimize bioprocesses.Increasing the electrochemical stability window and working temperature range of supercapacitor aqueous electrolyte is the major task in order to advance aqueous electrolyte-based supercapacitors. Here, a supramolecular induced new electrolyte of lithium bis(trifluoromethanesulfonyl) imide (LiTFSI) in dimethyl sulfoxide (DMSO) and water co-solvent system is proposed. Adjusting the coordination structure among LiTFSI, DMSO, and water in the electrolyte via supramolecular interactions results in its high ionic conductivity, low viscosity, wide electrochemical stability window, and large working temperature range. The new electrolyte-based supercapacitors can work in 2.40 V working potential and 130 °C working-temperature range from -40 to 90 °C. The devices exhibit good electrochemical performances, especially the energy density over 21 Wh kg-1, which is much higher than that with traditional aqueous electrolytes ( less then 10 Wh kg-1). The work paves a way to develop high-performance aqueous electrolytes for supercapacitors.